bcl-2 Expression in Breast Cancer
Author Information
Author(s): Russell D. Leek, Loukas Kaklamanis, Francesco Pezzella, Kevin C. Gatter, Adrian L. Harris
Primary Institution: University of Oxford
Hypothesis
The study investigates the expression of bcl-2 protein in human breast carcinomas and its relationship with established prognostic indicators.
Conclusion
Loss of bcl-2 expression in breast cancer is associated with poor prognostic markers and may indicate an ER-negative, EGFR-positive phenotype.
Supporting Evidence
- 80% of bcl-2-positive tumours were also ER positive.
- 70% of bcl-2-negative tumours were ER positive.
- 30% of bcl-2-positive tumours were EGFR positive.
- 70% of bcl-2-negative tumours were EGFR positive.
- Loss of bcl-2 expression is associated with poor prognostic markers.
Takeaway
This study looked at a protein called bcl-2 in breast cancer and found that when this protein is missing, it can mean the cancer is more likely to be aggressive.
Methodology
The study used immunohistochemistry to assess bcl-2 expression in breast carcinoma specimens.
Participant Demographics
The study included 111 patients with breast carcinoma, with a mix of pre- and post-menopausal women.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website